Table 8.
Injury
| Author, year {refid} | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator | Outcomes | Conclusions from data | AMSTAR-2 rating |
|---|---|---|---|---|---|---|---|---|
| Snedecor, 2013 [29] | To Dec 2011; 5 | Industry | 1 | NP associated with spinal cord injury |
I: Synthetic cannabinoids C: Placebo |
• NP • All-cause discontinuation |
Favors control for NP; no statistically significant different between groups for all-cause discontinuation | CL |
| Mehta, 2016 [35] | 2009–Sept 2015; 4 | NR | 2 | Spinal cord injury |
I: Plant-derived and Synthetic cannabinoids C: diphenhydramine |
• NP • Spastic pain |
Reported SBS | L |
| Meyer, 2010 [55] | 1980–2008; 4 | NR | 2 | Acquired brain injury |
I: Synthetic cannabinoids C: Placebo |
• Intercranial pressure • Glasgow outcome scale • Disability rating scale • Mortality rates • Activities of daily living • QoL |
Reported SBS | M |
| Wheaton, 2009 [76] | Jan 1980 to May 2008; 2 | Non-profit | 2 | Traumatic brain injury |
I: Synthetic cannabinoids C: placebo |
• Global outcome score (3 and 6 months) | No statistically significant difference between groups | CL |
NP neuropathic pain, NR not reported, QoL quality of life, SBS study-by-study